On the stock market since 2021, it operates in the world of health and science. It has 50,477 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
An investor who bought at the very peak is down 88% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $500K a year. A small number, but proof the product has real buyers.
A loss of $7.3M against $500K in annual sales.
The stock sits at $0.05. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 687.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, ZHCLF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ZHCLF is a high-risk stock — not yet profitable, and its future rides on its product catching on.